Abingdon Health PLC on Thursday reported a widened loss in the year that ended June 30 as revenue fell sharply.
Oxford-based company is an international developer and manufacturer of rapid diagnostics tests, such as lateral flow Covid tests.
Annual pretax loss widened to £21.6 million from £7.0 million a year ago. Revenue plummeted to £2.8 million from £11.6 million.
Meanwhile, cash at June 30 was £2.4 million but has since increased 83% to £4.4 million at the end of October.
‘Our key priorities are to grow our revenues and alongside this, given the economically uncertain outlook, reduce our cash-burn through continued close cost management. To this end we will focus our team’s activities on Contract Development & Manufacturing business and near-term revenues with own-product development being given less priority until we are closer to break-even,’ the firm said.
Noting the Covid pandemic of the past years, it added: ‘In this new environment, the board has confidence that Abingdon Health’s knowledge leadership position in the lateral flow industry and the development and manufacturing platform we have built will begin to yield positive momentum and revenue growth. Our key objective is to move the company to positive cash flow. ’
Looking forward, Abingdon was hopeful that as barriers to adopting the technology were reduced, there could be increased growth in the lateral flow industry across non-Covid applications, potentially boosting revenue.
Abingdon Health shares fell 17% to 5.00 pence each on Thursday morning in London.
Copyright 2022 Alliance News Limited. All Rights Reserved.
